Stock Events

Stock Events

Madrigal Pharmaceuticals 

€412
50
-€4-0.96% Monday 14:29

Statistics

Day High
453.6
Day Low
412
52W High
498.3
52W Low
259.5
Volume
14
Avg. Volume
0
Mkt Cap
9.36B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MarExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-4.42
-3.21
-1.99
-0.78
Expected EPS
-0.7768876478300001
Actual EPS
N/A

Financials

-256.91%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
343.33MRevenue
-882.06MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1MDGL.MI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is developing therapies for metabolic and endocrine disorders, directly competing with Madrigal's NASH treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong focus on liver diseases, including NASH, positioning it as a competitor in the same therapeutic area as Madrigal.
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
Galmed Pharmaceuticals is developing treatments for liver diseases, including NASH, making it a direct competitor to Madrigal.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals focuses on metabolic disorders, competing in the same space as Madrigal's treatments for liver diseases.
FibroGen
FGEN
Mkt Cap44.97M
FibroGen is involved in the discovery and development of therapies for liver diseases, including NASH, competing with Madrigal.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics, while primarily focused on CNS disorders, has interests in metabolic disorders, potentially putting it in competition with Madrigal.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for liver diseases, making it a potential competitor to Madrigal in the NASH space.

About

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Show more...
CEO
Mr. William J. Sibold
Employees
528
Country
US
ISIN
US5588681057

Listings

MI
IT
1MDGL.MI
LSE
GB
0JXI.LSE
XNAS
US
MDGL
F
DE
YDO1.F

0 Comments

Share your thoughts

FAQ

What is Madrigal Pharmaceuticals stock price today?▼
The current price of 1MDGL.MI is €412 EUR — it has decreased by -0.96% in the past 24 hours. Watch Madrigal Pharmaceuticals stock price performance more closely on the chart.
What is Madrigal Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Madrigal Pharmaceuticals stocks are traded under the ticker 1MDGL.MI.
What is Madrigal Pharmaceuticals market cap?▼
Today Madrigal Pharmaceuticals has the market capitalization of 9.36B
When is the next Madrigal Pharmaceuticals earnings date?▼
Madrigal Pharmaceuticals is going to release the next earnings report on March 04, 2026.
What were Madrigal Pharmaceuticals earnings last quarter?▼
1MDGL.MI earnings for the last quarter are -4.42 EUR per share, whereas the estimation was -1.99 EUR resulting in a -122.31% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Madrigal Pharmaceuticals revenue for the last year?▼
Madrigal Pharmaceuticals revenue for the last year amounts to 343.33M EUR.
What is Madrigal Pharmaceuticals net income for the last year?▼
1MDGL.MI net income for the last year is -882.06M EUR.
How many employees does Madrigal Pharmaceuticals have?▼
As of February 03, 2026, the company has 528 employees.
In which sector is Madrigal Pharmaceuticals located?▼
Madrigal Pharmaceuticals operates in the Health Care sector.
When did Madrigal Pharmaceuticals complete a stock split?▼
Madrigal Pharmaceuticals has not had any recent stock splits.
Where is Madrigal Pharmaceuticals headquartered?▼
Madrigal Pharmaceuticals is headquartered in West Conshohocken, US.